TY - JOUR AU - Zhang, Zheng AU - Xu, Ming-hua AU - Wei, Feng-ju AU - Shang, Li-na PY - 2020/08/20 Y2 - 2024/03/29 TI - Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis JF - Pakistan Journal of Medical Sciences JA - Pak J Med Sci VL - 36 IS - 6 SE - Original Articles DO - 10.12669/pjms.36.6.2945 UR - https://pjms.org.pk/index.php/pjms/article/view/2945 SP - AB - Objective: To evaluate the efficacy of atorvastatin combined with febuxostat in the treatment of gout patients with carotid atherosclerosis and to observe the effects on serum tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and C-reactive protein (CRP) levels, carotid plaques, and the adverse reactions.Methods: Seventy patients with gout and carotid atherosclerosis admitted to Affiliated Hospital of Hebei University from January 2014 to June 2017 were randomly divided into a treatment group and a control group. The treatment group received oral febuxostat 40 mg/day combined with atorvastatin 40 mg/day. The control group was given 40 mg/day febuxostat combined with 20 mg/day atorvastatin for 90 days. The effects of treatment on TNF-α, IL-1β, and CRP levels and carotid plaques of the patients were observed.Results: After 90 days of treatment, serum TNF-α, IL-1β, and CRP levels, as well as HUA and total cholesterol (TC), decreased in both groups after treatment. There were significant differences observed (p < 0.05). The carotid artery plaques in the two groups were significantly smaller after treatment (P<0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05).Conclusion: Double doses of atorvastatin combined with febuxostat can effectively reduce uric acid to improve the inflammatory state in patients and reduce carotid plaques without increasing the incidence of adverse reactions.doi: https://doi.org/10.12669/pjms.36.6.2945How to cite this:Zhang Z, Xu MH, Wei FJ, Shang LN. Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci. 2020;36(6):1334-1338. doi: https://doi.org/10.12669/pjms.36.6.2945This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ER -